Fig. 1From: Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinomaFlowchart for the identification of the mutation panel. Mutation data for coding sequences (CDSs) in TCGA from 486 patients was used to develop a CDS mutation panel for estimating the tumour mutation burden. The performance of the CDS mutation panel was validated in two datasets with data on progression-free survival for patients treated with immune checkpoint inhibitorsBack to article page